2008
Clinically Tolerated Strategies for NMDA Receptor Antagonism
Vincent Chen H, Zhang D, Lipton S. Clinically Tolerated Strategies for NMDA Receptor Antagonism. The Receptors 2008, 327-361. DOI: 10.1007/978-1-59745-055-3_8.Peer-Reviewed Original ResearchExcessive NMDAR activityNMDAR activityClinical trialsGlutamate receptorsSide effectsNeurologic disordersNervous systemAcute hypoxic-ischemic brain injuryGeneralized inhibitionAlzheimer's diseaseSecond-generation memantine derivativesHypoxic-ischemic brain injuryPhase 3 clinical trialsExcessive NMDAR activationSevere neuropathic painExcitatory amino acidsGlutamate-mediated neurotoxicityGlutamate receptor subtypesChronic neurodegenerative diseasesSystemic side effectsMajor excitatory transmitterNormal functionNMDA receptor antagonismGreater neuroprotective propertiesCentral nervous system
2006
Mechanism‐Based Development of Memantine as a Therapeutic Agent in Treating Alzheimer's Disease and Other Neurologic Disorders: Low‐Affinity, Uncompetitive Antagonism with Fast Off‐Rate
Chen H, Lipton S. Mechanism‐Based Development of Memantine as a Therapeutic Agent in Treating Alzheimer's Disease and Other Neurologic Disorders: Low‐Affinity, Uncompetitive Antagonism with Fast Off‐Rate. 2006, 439-464. DOI: 10.1002/9780470131862.ch18.Peer-Reviewed Original Research
1998
A phase I/II trial of nimodipine for HIV-related neurologic complications
Navia B, Dafni U, Simpson D, Tucker T, Singer E, McArthur J, Yiannoutsos C, Zaborski L, Lipton S. A phase I/II trial of nimodipine for HIV-related neurologic complications. Neurology 1998, 51: 221-228. PMID: 9674806, DOI: 10.1212/wnl.51.1.221.Peer-Reviewed Original ResearchConceptsAIDS dementia complexVoltage-dependent calcium channel antagonistsPhase I/II trialSevere AIDS-dementia complexHigh-dose armPhase II studyFurther clinical trialsCalcium channel antagonistsNPZ-8Adjuvant treatmentAntiretroviral therapyII trialNeurologic complicationsNeuropsychological z scoresNeuronal injuryHIV infectionPeripheral neuropathyTreat analysisCSF levelsDementia complexImmune activationClinical trialsNeurologic disordersChannel antagonistsPossible efficacy
1995
Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures.
Bonfoco E, Krainc D, Ankarcrona M, Nicotera P, Lipton S. Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures. Proceedings Of The National Academy Of Sciences Of The United States Of America 1995, 92: 7162-7166. PMID: 7638161, PMCID: PMC41299, DOI: 10.1073/pnas.92.16.7162.Peer-Reviewed Original ResearchConceptsForm of neurotoxicityN-methyl-D-aspartate receptor-mediated neurotoxicityCell damageChronic neurologic disordersNeuronal cell damageCortical cell culturesFinal common pathwayNitric oxide/Superoxide dismutaseS-nitrosocysteineAIDS dementiaNecrotic cell damageFocal ischemiaAcute swellingInitial insultCortical neuronsNeurologic disordersAlzheimer's diseaseNitric oxideNMDANeurodegenerative diseasesHuntington's diseaseIntense exposureNeurotoxicityCommon pathway
1989
Growth Factors for Neuronal Survival and Process Regeneration: Implications in the Mammalian Central Nervous System
Lipton S. Growth Factors for Neuronal Survival and Process Regeneration: Implications in the Mammalian Central Nervous System. JAMA Neurology 1989, 46: 1241-1248. PMID: 2573331, DOI: 10.1001/archneur.1989.00520470113038.Peer-Reviewed Original ResearchConceptsNeuronal survivalClinical neurologistsMammalian central nervous systemCentral nervous systemPossible therapeutic approachesPotential clinical implicationsImmunodeficiency syndromeAxonal regenerationNeuronal transplantationNeurologic disordersTherapeutic approachesModulatory agentsNervous systemAlzheimer's diseaseClinical implicationsMammalian brainNerve growthNeuronal processesGrowth factorNeurologistsNumber of substancesDiseaseNeuronsProcess regenerationSurvival